

Online Resource 2: Excluded Studies

Author and Year	Reason for exclusion
Amminger et al. 2022 [1]	Patient population not applicable - no primary mental health conditions diagnosis
Andries, Frystyk, Flyvbjerg & Stoving 2014 [2]	Intervention outside of scope - synthetic cannabinoids
Andries, Gram & Støving 2015 [3]	Intervention outside of scope - synthetic cannabinoids
Bhattacharyya 2018 [4]	Patient population not applicable - no primary mental health conditions diagnosis
Bisaga et al. 2015 [5]	Intervention outside of scope - synthetic cannabinoids
Boggs et al. 2012 [6]	Intervention outside of scope - synthetic cannabinoids
Bricker et al. 2007 [7]	Intervention outside of scope - nonmedicinal cannabis
Crippa et al. 2021 [8]	Incorrect study design - open-label trial
de Faria et al. 2020 [9]	Patient population not applicable - MH symptoms secondary to Parkinson's diagnosis
Fabre & McLendon 1981 [10]	Intervention outside of scope - synthetic cannabinoids
Gilman et al. 2022 [11]	Intervention outside of scope - Marijuana card ownership, all participants could choose cannabis products from a dispensary, the dose, and the frequency of use.
Hall et al. 2024 [12]	Patient population not applicable - no primary mental health conditions diagnosis
Hebert et al. 2024 [13]	Outcomes outside of interest - Anandamide Plasma Concentration, did not measure change in MH symptoms

Hill et al. 2017 [14]	Intervention outside of scope - synthetic cannabinoids
Hindocha et al. 2018 [15]	Patient population not applicable - no primary mental health conditions diagnosis
Hua et al. 2023 [16]	Outcomes outside of interest - Anandamide Plasma Concentration, did not measure change in MH symptoms
Jetly, Heber, Fraser & Boisvert 2015 [17]	Intervention outside of scope - synthetic cannabinoids
Kelly et al. 2011 [18]	Intervention outside of scope - synthetic cannabinoids
Leen-Feldner, Bynion, Eglit, Bonn-Miller, Gournay & Feldner 2022 [19]	Patient population not applicable - no primary mental health conditions diagnosis
Levin, Mariani, Brooks, Pavlicova, Cheng & Nunes 2011 [20]	Intervention outside of scope - synthetic cannabinoids
Lintzeris et al. 2019 [21]	Intervention outside of scope - synthetic cannabinoids
Lofwall, Babalonis, Nuzzo, Elayi & Walsh 2016 [22]	Intervention outside of scope - synthetic cannabinoids
Lundahl & Greenwald 2015 [23]	Intervention outside of scope - synthetic cannabinoids
Meltzer, Arvanitis, Bauer & Rein 2004 [24]	Intervention outside of scope - synthetic cannabinoids
Mills et al. 2022 [25]	Outcomes outside of interest - correlates of treatment engagement rather than safety and efficacy
Montebello et al. 2022 [26]	Patient population not applicable - mental health conditions secondary to refractory spasticity caused by multiple sclerosis
Morissette et al. 2021 [27]	Outcomes outside of interest - the concentrations of cytokines and the percentages of monocytes rather than safety and efficacy
Müller-Vahl, Koblenz, Jöbges, Kolbe, Emrich & Schneider 2001 [28]	Intervention outside of scope - synthetic cannabinoids

Robinson et al. 2018 [29]	Intervention outside of scope - synthetic cannabinoids
Schlienz, Lee, Stitzer & Vandrey 2018 [30]	Intervention outside of scope - synthetic cannabinoids
Tonstad & Aubin 2012 [31]	Intervention outside of scope - synthetic cannabinoids
Vandrey, Stitzer, Mintzer, Huestis, Murray & Lee 2013 [32]	Intervention outside of scope - synthetic cannabinoids
Zabik & Lauren 2023 [33]	Intervention outside of scope - synthetic cannabinoids
Zabik, Rabinak, Peters & Ladipaolo 2023 [34]	Intervention outside of scope - synthetic cannabinoids